ABSTRACT OF THE DISCLOSURE
The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
公开内容摘要
本发明的钉钉肽及其药学上可接受的盐类是胰高血糖素受体和 GLP-1 受体的共拮抗剂,可用于治疗、预防和抑制由胰高血糖素受体和 GLP-1 受体介导的疾病,包括但不限于糖尿病、非
酒精性脂肪肝(NAFLD)、非
酒精性脂肪性肝炎(NASH)和肥胖症等代谢性疾病。